© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
David Hutton
Articles
Research suggests link between long COVID-19 and corneal nerve damage
July 28, 2021
Article
A team of investigators used corneal confocal microscopy to identify corneal nerve damage in cases of long COVID-19.
Optogenetic gene therapy trial begins, first patient dosed
July 26, 2021
Article
Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.
Laser imaging system may offer early detection, treatment for eye diseases that cause blindness
June 18, 2021
Article
According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.
Outlook Therapeutics approaching FDA approval of bevacizumab-vikg for wet AMD treatment
May 31, 2021
Article
The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.